Related references
Note: Only part of the references are listed.A Critical Review of the Effectiveness of Rodent Pharmaceutical Carcinogenesis Testing in Predicting for Human Risk
C. L. Alden et al.
VETERINARY PATHOLOGY (2011)
Cancer Risk Assessment Approaches at the FDA/CDER: Is the Era of the 2-Year Bioassay Drawing to a Close?
David Jacobson-Kram
TOXICOLOGIC PATHOLOGY (2010)
An Industry Perspective on the Utility of Short-Term Carcinogenicity Testing in Transgenic Mice in Pharmaceutical Development
Richard D. Storer et al.
TOXICOLOGIC PATHOLOGY (2010)
Alternative Mouse Models for Carcinogenicity Assessment: Industry Use and Issues with Pathology Interpretation
Gerald G. Long et al.
TOXICOLOGIC PATHOLOGY (2010)
Carcinogenic comparative study on rasH2 mice produced by two breeding facilities
Kazuhiko Machida et al.
JOURNAL OF TOXICOLOGICAL SCIENCES (2008)
Carcinogenic susceptibility of rasH2 mice to troglitazone
Meilan Jin et al.
ARCHIVES OF TOXICOLOGY (2007)
The utility of genetically modified mouse assays for identifying human carcinogens: A basic understanding and path forward
J MacDonald et al.
TOXICOLOGICAL SCIENCES (2004)
PCR method for genotyping and zygosity-testing of RasH2 transgenic mice
H Suemizu et al.
EXPERIMENTAL ANIMALS (2004)
CB6F1-rasH2 mouse: Overview of available data
T Usui et al.
TOXICOLOGIC PATHOLOGY (2001)
Share Paper
